New treatment with bovine lactoferrin and piroxicam helps cats

Abstract

Feline lymphocytic-plasmacytic gingivitis/stomatitis (LPGS) or caudal stomatitis is an inflammatory disease that causes painfully erosive lesions and proliferations of the oral mucosa. The disease is difficult to cure and can affect cats at an early age, resulting in lifetime therapy. In this study, a new treatment using a combination of bovine lactoferrin (bLf) oral spray and oral piroxicam was investigated using a randomized double-blinded clinical trial in 13 cats with caudal stomatitis. Oral lesion grading and scoring of clinical signs were conducted during and after the trial to assess treatment outcome. Oral mucosal biopsies were used to evaluate histological changes during and after treatment. Clinical signs were significantly improved in 77% of the cats. In a 4-week study, clinical signs were considerably ameliorated by oral piroxicam during the first 2&#x2009;weeks. In a 12-week study, the combined bLf oral spray and piroxicam, when compared with piroxicam alone, exhibited an enhanced effect that reduced the severity of the oral lesions (P&#x2009;=&#x2009;0.059), while also significantly improving clinical signs (P&#x2009;<0.05), quality of life (P&#x2009;<0.05), and weight gain (P&#x2009;<0.05). The remission of oral inflammation was closely correlated with the decreased number of macrophages (OR&#x2009;=&#x2009;4.719, P&#x2009;<&#x2009;0.05). There was no detectable influence on liver or kidney function during a 12-week assessment. It was concluded that combining oral bLf spray and piroxicam was safe and might be used to decrease the clinical signs of caudal stomatitis in cats.